Spotlight

Is COVID-19 a Perfect Storm for Parkinson’s Disease?

Patrik Brundin,1,* Avindra Nath,2 and J. David Beckham3

Three recent case reports (by Méndez-Guerrero et al., Cohen et al., and Faber et al.) describe the development of acute parkinsonism following coronavirus disease 2019 (COVID-19). We discuss possible underlying cellular and molecular mechanisms, and whether COVID-19 might be associated with elevated long-term risk of Parkinson’s disease (PD).

The COVID-19 pandemic has greatly impacted global health, with an estimated 39 million confirmed cases and 1.1 million deaths (as of October 16, 2020). Additionally, several COVID-19 patients have experienced long-term illness and residual symptoms even after the virus was no longer detectable. Here, we discuss whether COVID-19 is associated with an elevated risk of developing PD, either imminently after the viral infection or after several years.

The progressive neurodegenerative disorder, PD, is characterized by a range of motor and non-motor symptoms [1]. Years, or even decades, before the onset of the classical motor symptoms, the PD process is associated with a characteristic prodrome. The pathology in PD includes the loss of midbrain dopamine neurons, neuroinflammation, and development of intraneuronal protein aggregates (Lewy bodies, rich in α-synuclein) in numerous brain regions [1]. Genetic studies suggest that ~5% of PD cases are familial, and the heritability in sporadic cases is believed to be ~25%. Aging is the most prominent risk factor, and analysis of genes associated with PD risk has implicated multiple cellular dysfunctions, including immune system regulation and protein homeostasis. Biomarker studies also support an ongoing systemic inflammation in PD, and immune system disorders are associated with elevated PD risk. While the initial trigger(s) of sporadic PD are largely unknown, bacterial and viral infections have been implicated in some cases [2].

Notably, at least three published single-case reports indicate that patients with COVID-19 have developed clinical parkinsonism, either in isolation or with other neurological deficits, within 2–5 weeks of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [3-5]. They were aged 35, 45, and 58 years and all three had severe respiratory infection requiring hospitalization. Two of the three patients responded with reduced parkinsonian symptoms upon administration of traditional dopaminergic medication [4,5], and the third patient recovered spontaneously [3]. In all cases, brain imaging revealed reduced function of the nigrostriatal dopamine system, akin to PD. None of them had a family history of PD, or a history with signs of prodromal PD; one patient underwent genetic testing but did not carry any PD risk variants [4].

These cases do not prove a causal relationship between SARS-CoV-2 infection and the development of parkinsonism. Possibly, the reported patients were destined to develop PD, were on the cusp of losing the number of nigral dopamine neurons required for the emergence of motor symptoms, and the viral infection only accelerated an ongoing neurodegenerative process around a critical timepoint. However, the rapid onset of severe motor symptoms in close temporal proximity to the viral infection is still suggestive of a causal link. Furthermore, none of the reported patients exhibited signs of prodromal PD before contracting COVID-19. There are no descriptions of neuropathology in patients who developed parkinsonism acutely following SARS-CoV-2 infection. However, perhaps something can be gleaned from a growing number of postmortem reports describing those dying with COVID-19 without parkinsonism. Notably, one such neuropathology study of 43 patients found evidence of microglial activation and invasion of cytotoxic T cells in the brainstem [6], which are neuropathological signs also associated with PD.

We propose three potential mechanisms for the rapid development of parkinsonism following SARS-CoV-2 infection (Figure 1). These mechanisms may operate either alone or in concert. First, vascular insults have been reported to develop in multiple organs, including the brain, in severe COVID-19 in conjunction with a hypercoagulable state [7]. This could conceivably directly damage the nigrostriatal system, akin to what is seen in vascular parkinsonism. However, the aforementioned recent autopsy study [6] did not report any bleeding or small vessel thrombosis in the brain.

Second, considering the association between inflammatory disorders and elevated PD risk, it is possible that marked systemic inflammation caused by severe COVID-19 could trigger neuroinflammation and demise of nigral dopamine neurons. Midbrain dopamine neurons are believed to be particularly susceptible to systemic inflammation. Several studies have demonstrated elevated interleukin (IL)-6 levels in COVID-19, and one report suggested that the kynurenine pathway is perturbed [8]. Interestingly, these are both mechanisms that have been associated with PD [2,9].

Third, SARS-CoV-2 may be a neurotropic virus, because viral RNA has been detected in postmortem brains of some patients with COVID-19. Furthermore, neuropathological studies using immunostaining for aggregated

---

* Corresponding author.

1. Department of Neurology, Karolinska Institutet, Stockholm, Sweden; 2. Department of Neuroscience, National Institute on Aging, National Institutes of Health, Bethesda, Maryland; 3. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

1. References

[1] J. Holton et al., Trends Neurosci. 38, 575 (2015).
[2] K. Arai et al., Brain 143, 640 (2020).
[3] J. Beckman et al., Neuron 107, 1078 (2020).
[4] S. S. Cohen et al., Lancet Neurol. 19, 836 (2020).
[5] A. Méndez-Guerrero et al., Acta Neurol. Scand. 142, 436 (2020).
[6] M. Brundin et al., Brain 143, 1785 (2020).
[7] N. G. K. Abraham et al., Stroke 51, 2924 (2020).
[8] J. A. Blomgren et al., Cell 183, 284 (2020).
[9] J. A. Beal, Ann. Neurol. 58, 151 (2005).

© 2020 Cell Press
α-synuclein have suggested that the PD process starts in the olfactory system or in enteric nerves and then propagates along neural pathways to additional brain regions [1]. Indeed, hyposmia and constipation are common features of prodromal PD, and α-synuclein aggregates might contribute to their pathophysiology [1]. Strikingly, hyposmia (and dysgeusia) are common in COVID-19, and SARS-CoV-2 can infect the gastrointestinal tract, suggesting that the virus gains direct access to brain regions relevant to PD via these routes. Additionally, the respiratory tract is innervated by the vagus nerve, which may be yet another portal for viral entry into the brain. Furthermore, midbrain dopamine neurons express high levels of the angiotensin-converting enzyme 2 (ACE2) receptor, which is essential for viral entry [10]. An intriguing possibility is that the neuroinvasion of SARS-CoV-2 leads to an upregulation of neuronal α-synuclein. Such an increase in α-synuclein has been observed following infection with West Nile virus [11] and Western Equine Encephalitis virus [12], and animals lacking neuronal α-synuclein are more susceptible to West Nile virus encephalitis compared with those with this protein [11]. These findings suggest that α-synuclein expression increases during viral infection of the nervous system and acts as a viral restriction factor. In COVID-19, it is possible that sustained elevated levels of intraneuronal α-synuclein lead to the formation of aggregates, similar to the PD brain, possibly followed by neuronal death.

If this latter paradigm is correct, SARS-CoV-2 could predispose to the development of PD later in life. Experimental studies, and findings in families with α-synuclein gene multiplications, indicate that sustained elevated α-synuclein levels promote aggregation of the protein [1]. Superimposed on this, long-term systemic and/or neuroinflammation due to COVID19, might be ‘a perfect storm’ for the development of PD.

Thus, while acute parkinsonism in conjunction with COVID-19 appears to be rare, spread of SARS-CoV-2 widely in society might lead to a high proportion of patients being predisposed to developing PD later in life, especially because they will also be affected by normal aging processes (Figure 1). Therefore, it is important to carefully follow large cohorts of patients affected by COVID-19, and monitor them for manifestations of PD. If patients with SARS-CoV-2 have an increased risk for PD, and potentially other related neurodegenerative disorders, it will be critical to identify treatments that mitigate such an elevated risk. A link between COVID-19 and PD would also imply that attaining ‘herd immunity’ by naturally infecting a large portion of the population could have disastrous long-term implications.

Acknowledgements
P.B. is supported by funding from Van Andel Institute and the Farmer Family Foundation on projects related to infections and PD. A.N. is supported by the Division of...
Spotlight
This Is Your Brain on (Low) Glucose
Patrick Miller-Rhodes,1,2 Harris A. Gelbard,1,2,3,4,5,* and Niccolò Terrando1,6,*

Brain functioning and high-order cognitive functions critically rely on glucose as a metabolic substrate. In a recent study, Kealy et al. investigated the impact of glucose availability on sickness behavior and delirium in mice and humans. They identified disrupted brain carbohydrate metabolism as a key mechanistic driver of these behaviors.

Metabolic processes support all biological functions. Various environmental constraints force organisms to prioritize certain metabolic programs over others to achieve optimal outcomes [1]. Abundant nutrients (e.g., glucose) drive growth and reproduction through anabolic processes, or energy production; by contrast, a lack of nutrients prioritizes catabolic processes, or energy breakdown. However, the metabolic processes that support immune responses are less straightforward. Inflammation can perturb cognition. For example, patients with a hip fracture frequently experience delirium, which is characterized by impaired attention and reduced level of consciousness during the perioperative period [2]. However, whereas the specific cause of infectious inflammation is often well defined (i.e., a certain pathogen), delirium is a complex clinical state with multiple etiologies. In fact, delirium can arise from a range of precipitating factors, including trauma, major surgery, use of psychoactive drugs, and metabolic abnormalities [3]. Yet, not all major surgeries, to name one example, cause delirium. An individual’s vulnerability to delirium depends on various predisposing factors, including pre-existing cognitive impairment, advanced age, history of stroke, and medication [3]. Despite this dizzying array of predisposing and precipitating factors, a recent paper by Kealy et al. [4] pegged disrupted carbohydrate metabolism as the proximate cause of delirium resulting from systemic inflammation in mice and humans.

Conventional wisdom dictates that inflammatory cytokines perpetrate sickness behaviors via actions at the blood–brain barrier and beyond it [5]. Kealy et al. [4] questioned whether inflammatory cytokines were in fact the proximate cause of these behaviors by exploring the glycemic and behavioral effects of systemic inflammation in mice using lipopolysaccharide (LPS) as an inflammatory stimulus. Intraperitoneal injection of LPS decreased glucose levels in the blood and cerebrospinal fluid (CSF), with kinetics that mirrored reductions in spontaneous behavior. The behavioral effect of LPS was also reduced by glucose supplementation and enhanced by 2-deoxyglucose, a glycolytic inhibitor. Interestingly, IL-1β alone

References
1. Poeoe, W. et al. (2017) Parkinson disease. Nat. Rev. Dis. Primers 3, 17013
2. Johnson, M.E. et al. (2019) Triggers, facilitators, and aggravators: redefining Parkinson’s disease pathogenesis. Trends Neurosci. 42, 4–13
3. Méndez-Guerrero, A. et al. (2020) Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology 95, e2109–e2118. https://doi.org/10.1212/ WNL.0000000000010282
4. Cohen, M.E. et al. (2020) A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol. 19, 804–806. https://doi.org/10.1016/S1474-4422(20)30005-7
5. Faber, I. et al. (2020) Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov. Disorder. 35, 1721–1722. https://doi.org/10.1002/mds.29277
6. Matschke, J. et al. (2020) Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. Published online October 5, 2020. https://doi.org/10.1016/S1474-4422(20)30008-2
7. Fabbri, V.P. et al. (2020) Brain ischemic injury in COVID-19 infected patients: a series of 10 post-mortem cases. Brain Pathol. Published online October 1, 2020. http://dx.doi.org/10.1111/bpa.12901
8. Thomas, T. et al. (2020) COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 5, e140327
9. Hellman, P.L. et al. (2020) Trypophobia metabolites are associated with symptoms and rinal pathology in Parkinson’s disease. Mov. Disorder. Published online July 25, 2020. https://doi.org/10.1002/mds.29202
10. Yang, L. et al. (2020) A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell 27, 125–136
11. Beatman, E.L. et al. (2015) Alpha-synuclein expression restricts RNA viral infections in the brain. J. Virol. 90, 2767–2782
12. Bante, C.M. et al. (2019) Infection with mosquito-borne alphaviruses induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. NPL. Parkinsons Dis. 5, 20

Disclaimer Statement
P.B. has received commercial support as a consultant from Axial Biotherapeutics, Calico Life Sciences, Curasen, Fujifilm-Cellular Dynamics International, Idorsia, IOS Press Partners, LifeScience Capital LLC, Lundbeck A/S, and Living Cell Technologies Ltd. He received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics, and is on the steering committee of the NLLO-PD trial.

1Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA
2Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
3Division of Medicine, Neurology and Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

*Correspondence: Patrik.Brundin@va.org (P. Brundin).
https://doi.org/10.1016/j.tins.2020.10.009
© 2020 Elsevier Ltd. All rights reserved.